A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Healthy adults ages 18 to 50

Diagnosis Required

None

Diseases Being Studied

HIV Prevention

Clinical Trials.gov reference NCT05001373

First in-human trial for a HIV vaccine using the mRNA platform.

Meet Your Clinical Research Team

Contact us

Principal Investigator: Local PI: Barbara Taylor, MD, MS

For more information on this study, please contact Dr. Barbara Taylor at taylorb4@uthscsa.edu